Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.40 |
| ▸ | CNR1 | P21554 | 11/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653176 | 0.89 | HDAC6 (0.39) | CNR2CNR1LMNAMAPK1KMT2A | |
| SCHEMBL5649155 | 0.84 | HDAC6 (0.44) | CNR2CNR1LMNAKMT2AHDAC6 | |
| SCHEMBL5651985 | 0.81 | PRSS12 (0.54) | CNR2CNR1PTGDR2PRSS12HDAC6 | |
| SCHEMBL5651035 | 0.80 | PRSS12 (0.42) | CNR2CNR1PRSS12 | |
| SCHEMBL5649026 | 0.79 | DGAT1 (0.43) | HDAC6 | |
| SCHEMBL5653971 | 0.77 | AMY1A (0.42) | CNR2CNR1HCRTR1HCRTR2PTGDR2 | |
| SCHEMBL5647407 | 0.77 | CNR1 (0.41) | CNR2CNR1PRSS12HDAC6 | |
| SCHEMBL5652195 | 0.77 | FLT3 (0.45) | PTGDR2PRSS12 | |
| SCHEMBL5652805 | 0.76 | MEN1 (0.51) | LMNAKMT2A | |
| SCHEMBL5650908 | 0.76 | FOXO1 (0.43) | CNR2CNR1PRSS12HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | CNR2 129/4885CNR1 68/4885LMNA 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.